Savara (SVRA) Tops Q3 EPS by 10c

Savara (NASDAQ: SVRA) reported Q3 EPS of ($0.30), $0.10 better than the analyst estimate of ($0.40).

“Based on the totality of evidence, we continue to believe that Molgradex has a clinically meaningful treatment effect on aPAP and we are committed to this program,” said Rob Neville, Chief Executive Officer, Savara. “In the near-term, gaining clarity on the best regulatory path forward is our highest corporate priority and we look forward to further collaborating with the FDA and EMA in this regard.”

For earnings history and earnings-related data on Savara (SVRA) click here.

You May Also Be Interested In

• Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• Goldman Sachs Downgrades Bank Mandiri (BMRI:IJ) (PPERF) to Sell, 'Liquidity and capital tightness'